Astellas Pharma Inc. (TYO:4503)
Japan flag Japan · Delayed Price · Currency is JPY
2,699.00
+21.00 (0.78%)
Nov 13, 2026, 3:30 PM JST

Astellas Pharma Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Astellas Pharma stock has a consensus rating of "Buy" and an average price target of ¥2,597. The average 1-year stock price forecast is 3.77% lower than the current stock price, while the lowest is ¥2,000 (-25.90%) and the highest is ¥3,400 (+25.97%).

Price Target: ¥2,597 (-3.77%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price¥2,000¥2,597¥2,500¥3,400
Change-25.90%-3.77%-7.37%+25.97%

Analyst Ratings

The average analyst rating for Astellas Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy444444
Buy001111
Hold888888
Sell111111
Strong Sell000000
Total131314141414

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
Morgan Stanley
No rating
Morgan Stanley
Hold
Maintains
¥2,200 → ¥2,250
HoldMaintains¥2,200 → ¥2,250-16.64%Nov 5, 2026
Unknown Analyst
Macquarie
No rating
Macquarie
Buy
Maintains
¥2,700 → ¥2,900
BuyMaintains¥2,700 → ¥2,900+7.45%Nov 5, 2026
Unknown Analyst
Daiwa
No rating
Daiwa
Sell
Maintains
¥1,700 → ¥2,000
SellMaintains¥1,700 → ¥2,000-25.90%Sep 30, 2026
Unknown Analyst
Mizuho Securities
No rating
Mizuho Securities
Hold
Maintains
¥2,440
HoldMaintains¥2,440-9.60%Sep 14, 2026
Unknown Analyst
CLSA
No rating
CLSA
Buy
Maintains
¥3,000
BuyMaintains¥3,000+11.15%Aug 18, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
2.38T
from 2.14T
Increased by 11.47%
Revenue Next Year
2.22T
from 2.38T
Decreased by -6.76%
EPS This Year
214.01
from 162.22
Increased by 31.92%
EPS Next Year
208.03
from 214.01
Decreased by -2.80%
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingMar 31, 2022Mar 31, 2023Mar 31, 2024Mar 31, 2025Mar 31, 2026Mar 31, 2027
Revenue
1.30T1.52T1.60T1.91T2.14T2.38T
Revenue Growth
3.73%17.16%5.60%19.25%11.87%11.47%
Gross Profit
1.04T1.23T1.31T1.56T1.73T1.94T
Gross Margin
80.48%81.01%81.76%81.74%80.91%81.39%
Operating Income
218.15B231.65B124.61B263.54B439.28B523.94B
Net Income
124.09B98.71B17.05B50.75B291.54B380.42B
EPS
67.0554.099.4728.24162.22214.01
EPS Growth
3.31%-19.33%-82.49%198.21%474.43%31.92%
Forward PE
16.5015.8721.0618.7314.0812.61
Dividend / Share
50.0060.0070.0074.0078.0080.15
Dividend Growth
19.05%20.00%16.67%5.71%5.41%2.76%
Free Cash Flow
----493.47B479.50B
No. Analysts
-----13
Financial currency is JPY.

Revenue Forecast

Revenue202720282029
High2.5T
Avg2.4T
Low2.3T

Revenue Growth

Revenue Growth202720282029
High
15.8%
Avg
11.5%
Low
9.0%

EPS Forecast

EPS202720282029
High238.19
Avg214.01
Low191.60

EPS Growth

EPS Growth202720282029
High
46.8%
Avg
31.9%
Low
18.1%